SHU 555CAlternative Names: Ferumoxtran-10 - Bayer Schering Pharma; SH U 555 C; Supravist; Ultrasmall Superparamagnetic Ironoxide; USPIO
Latest Information Update: 13 Jul 2010
At a glance
- Originator Bayer Schering Pharma
- Class Contrast media; Ferric compounds; Glucans; Oxides
- Mechanism of Action Magnetic resonance imaging enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 13 Jul 2010 No development reported - Preregistration for Ischaemic heart disorders diagnosis in Sweden (IV)
- 21 Oct 2009 Regulatory discussions are ongoing with SHU 555C
- 31 Dec 2006 Preregistration for Ischaemic heart disorders (diagnosis) in Sweden (IV)